Stroma and pancreatic ductal adenocarcinoma: An interaction loop

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 1, 2012, Pages 170-178

  Luo, Guopei ^a,b   Long, Jiang ^a,b   Zhang, Bo ^a,b   Liu, Chen ^a,b   Xu, Jin ^a,b   Ni, Quanxing ^a,b   Yu, Xianjun ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Pancreatic ductal adenocarcinoma; Stroma; Targeted therapy; Tumor microenvironment

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; SARIDEGIB; SOMATOMEDIN C; SONIC HEDGEHOG PROTEIN; TANOMASTAT; TRANSFORMING GROWTH FACTOR BETA;

ACUTE PANCREATITIS; AGING; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL GROWTH; CHRONIC PANCREATITIS; CIGARETTE SMOKING; DIABETES MELLITUS; DIETARY INTAKE; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TUMOR LEVEL; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; LIPID DIET; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN DIET; RADIOSENSITIVITY; REVIEW; STROMA; STROMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; HUMANS; PANCREATIC NEOPLASMS; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84860281544     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.04.002     Document Type: Review

References (140)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Yu X., Zhang Y., Chen C., Yao Q., Li M. Targeted drug delivery in pancreatic cancer. Biochim. Biophys. Acta 2010, 1805:97-104.
3. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
4. Geer R.J., Brennan M.F. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am. J. Surg. 1993, 165:68-72. discussion 72-63.
5. Chu G.C., Kimmelman A.C., Hezel A.F., DePinho R.A. Stromal biology of pancreatic cancer. J. Cell. Biochem. 2007, 101:887-907.
6. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
7. Bailey J.M., Swanson B.J., Hamada T., Eggers J.P., Singh P.K., Caffery T., Ouellette M.M., Hollingsworth M.A. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin. Cancer Res. 2008, 14:5995-6004.
8. Bhowmick N.A., Chytil A., Plieth D., Gorska A.E., Dumont N., Shappell S., Washington M.K., Neilson E.G., Moses H.L. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303:848-851.
9. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
10. DeCosse J.J., Gossens C.L., Kuzma J.F., Unsworth B.R. Breast cancer: induction of differentiation by embryonic tissue. Science 1973, 181:1057-1058.
11. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3:453-458.
12. Hill R., Song Y., Cardiff R.D., Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005, 123:1001-1011.
13. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
14. Moinfar F., Man Y.G., Arnould L., Bratthauer G.L., Ratschek M., Tavassoli F.A. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res. 2000, 60:2562-2566.
15. Patocs A., Zhang L., Xu Y., Weber F., Caldes T., Mutter G.L., Platzer P., Eng C. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N. Engl. J. Med. 2007, 357:2543-2551.
16. Garrido-Laguna I., Uson M., Rajeshkumar N.V., Tan A.C., de Oliveira E., Karikari C., Villaroel M.C., Salomon A., Taylor G., Sharma R., Hruban R.H., Maitra A., Laheru D., Rubio-Viqueira B., Jimeno A., Hidalgo M. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin. Cancer Res. 2011, 17:5793-5800.
17. Wilson T.J., Singh R.K. Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases. Biochim. Biophys. Acta 2008, 1785:85-95.
18. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., Huhn R.D., Song W., Li D., Sharp L.L., Torigian D.A., O'Dwyer P.J., Vonderheide R.H. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
19. Hu M., Yao J., Cai L., Bachman K.E., van den Brule F., Velculescu V., Polyak K. Distinct epigenetic changes in the stromal cells of breast cancers. Nat. Genet. 2005, 37:899-905.
20. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54.
21. Garber K. Stromal depletion goes on trial in pancreatic cancer. J. Natl. Cancer Inst. 2010, 102:448-450.
22. Von Hoff D.D., Ramanathan R.K., Borad M.J., Laheru D.A., Smith L.S., Wood T.E., Korn R.L., Desai N., Trieu V., Iglesias J.L., Zhang H., Soon-Shiong P., Shi T., Rajeshkumar N.V., Maitra A., Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 2011, 29:4548-4554.
23. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., Frese K.K., Denicola G., Feig C., Combs C., Winter S.P., Ireland-Zecchini H., Reichelt S., Howat W.J., Chang A., Dhara M., Wang L., Ruckert F., Grutzmann R., Pilarsky C., Izeradjene K., Hingorani S.R., Huang P., Davies S.E., Plunkett W., Egorin M., Hruban R.H., Whitebread N., McGovern K., Adams J., Iacobuzio-Donahue C., Griffiths J., Tuveson D.A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
24. Farmer P., Bonnefoi H., Anderle P., Cameron D., Wirapati P., Becette V., Andre S., Piccart M., Campone M., Brain E., Macgrogan G., Petit T., Jassem J., Bibeau F., Blot E., Bogaerts J., Aguet M., Bergh J., Iggo R., Delorenzi M. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 2009, 15:68-74.
25. Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., Chen H., Omeroglu G., Meterissian S., Omeroglu A., Hallett M., Park M. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 2008, 14:518-527.
26. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315:1650-1659.
27. Mueller M.M., Fusenig N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4:839-849.
28. Farrow B., Sugiyama Y., Chen A., Uffort E., Nealon W., Mark Evers B. Inflammatory mechanisms contributing to pancreatic cancer development. Ann. Surg. 2004, 239:763-769. discussion 769-771.
29. Crnogorac-Jurcevic T., Efthimiou E., Capelli P., Blaveri E., Baron A., Terris B., Jones M., Tyson K., Bassi C., Scarpa A., Lemoine N.R. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 2001, 20:7437-7446.
30. Tomakidi P., Mirancea N., Fusenig N.E., Herold-Mende C., Bosch F.X., Breitkreutz D. Defects of basement membrane and hemidesmosome structure correlate with malignant phenotype and stromal interactions in HaCaT-Ras xenografts. Differentiation 1999, 64:263-275.
31. Zhu Z., Kleeff J., Kayed H., Wang L., Korc M., Buchler M.W., Friess H. Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Mol. Carcinog. 2002, 35:138-147.
32. Sangai T., Ishii G., Kodama K., Miyamoto S., Aoyagi Y., Ito T., Magae J., Sasaki H., Nagashima T., Miyazaki M., Ochiai A. Effect of differences in cancer cells and tumor growth sites on recruiting bone marrow-derived endothelial cells and myofibroblasts in cancer-induced stroma. Int. J. Cancer 2005, 115:885-892.
33. Apte M.V., Haber P.S., Applegate T.L., Norton I.D., McCaughan G.W., Korsten M.A., Pirola R.C., Wilson J.S. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. Gut 1998, 43:128-133.
34. Bachem M.G., Schneider E., Gross H., Weidenbach H., Schmid R.M., Menke A., Siech M., Beger H., Grunert A., Adler G. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 1998, 115:421-432.
35. Jaster R. Molecular regulation of pancreatic stellate cell function. Mol. Cancer 2004, 3:26.
36. Hwang R.F., Moore T., Arumugam T., Ramachandran V., Amos K.D., Rivera A., Ji B., Evans D.B., Logsdon C.D. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008, 68:918-926.
37. Duner S., Lopatko Lindman J., Ansari D., Gundewar C., Andersson R. Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. Pancreatology 2010, 10:673-681.
38. + pancreatic stellate cells enhance the progression of pancreatic cancer. Gastroenterology 2010, 139:1041-1051. 1051 e1041-1048.
39. Vonlaufen A., Joshi S., Qu C., Phillips P.A., Xu Z., Parker N.R., Toi C.S., Pirola R.C., Wilson J.S., Goldstein D., Apte M.V. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 2008, 68:2085-2093.
40. Schneider E., Schmid-Kotsas A., Zhao J., Weidenbach H., Schmid R.M., Menke A., Adler G., Waltenberger J., Grunert A., Bachem M.G. Identification of mediators stimulating proliferation and matrix synthesis of rat pancreatic stellate cells. Am. J. Physiol. Cell Physiol. 2001, 281:C532-C543.
41. Ohnishi N., Miyata T., Ohnishi H., Yasuda H., Tamada K., Ueda N., Mashima H., Sugano K. Activin A is an autocrine activator of rat pancreatic stellate cells: potential therapeutic role of follistatin for pancreatic fibrosis. Gut 2003, 52:1487-1493.
42. Mews P., Phillips P., Fahmy R., Korsten M., Pirola R., Wilson J., Apte M. Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis. Gut 2002, 50:535-541.
43. Jaster R., Sparmann G., Emmrich J., Liebe S. Extracellular signal regulated kinases are key mediators of mitogenic signals in rat pancreatic stellate cells. Gut 2002, 51:579-584.
44. Shek F.W., Benyon R.C., Walker F.M., McCrudden P.R., Pender S.L., Williams E.J., Johnson P.A., Johnson C.D., Bateman A.C., Fine D.R., Iredale J.P. Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis. Am. J. Pathol. 2002, 160:1787-1798.
45. Phillips P.A., McCarroll J.A., Park S., Wu M.J., Pirola R., Korsten M., Wilson J.S., Apte M.V. Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover. Gut 2003, 52:275-282.
46. Yoshida S., Ujiki M., Ding X.Z., Pelham C., Talamonti M.S., Bell R.H., Denham W., Adrian T.E. Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs. Mol. Cancer 2005, 4:27.
47. Omary M.B., Lugea A., Lowe A.W., Pandol S.J. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J. Clin. Invest. 2007, 117:50-59.
48. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 2002, 3:349-363.
49. Lazard D., Sastre X., Frid M.G., Glukhova M.A., Thiery J.P., Koteliansky V.E. Expression of smooth muscle-specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:999-1003.
50. Seton-Rogers S. Pancreatic cancer: fibroblast co-conspirators. Nat. Rev. Cancer 2011, 11:758.
51. Tjomsland V., Spangeus A., Valila J., Sandstrom P., Borch K., Druid H., Falkmer S., Falkmer U., Messmer D., Larsson M. Interleukin 1alpha sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia 2011, 13:664-675.
52. Bremnes R.M., Donnem T., Al-Saad S., Al-Shibli K., Andersen S., Sirera R., Camps C., Marinez I., Busund L.T. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J. Thorac. Oncol. 2010, 6:209-217.
53. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., Carey V.J., Richardson A.L., Weinberg R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
54. Sieuwerts A.M., Klijn J.G., Henzen-Logmand S.C., Bouwman I., Van Roozendaal K.E., Peters H.A., Setyono-Han B., Foekens J.A. Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-beta(1) (TGF beta(1)) compared with factor(s) released by human epithelial-carcinoma cells. Int. J. Cancer 1998, 76:829-835.
55. Li G., Satyamoorthy K., Meier F., Berking C., Bogenrieder T., Herlyn M. Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene 2003, 22:3162-3171.
56. Lewis M.P., Lygoe K.A., Nystrom M.L., Anderson W.P., Speight P.M., Marshall J.F., Thomas G.J. Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br. J. Cancer 2004, 90:822-832.
57. Maehara N., Matsumoto K., Kuba K., Mizumoto K., Tanaka M., Nakamura T. NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. Br. J. Cancer 2001, 84:864-873.
58. Sato N., Maehara N., Goggins M. Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res. 2004, 64:6950-6956.
59. Walter K., Omura N., Hong S.M., Griffith M., Vincent A., Borges M., Goggins M. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clin. Cancer Res. 2010, 16:1781-1789.
60. Yauch R.L., Gould S.E., Scales S.J., Tang T., Tian H., Ahn C.P., Marshall D., Fu L., Januario T., Kallop D., Nannini-Pepe M., Kotkow K., Marsters J.C., Rubin L.L., de Sauvage F.J. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455:406-410.
61. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
62. Murdoch C., Giannoudis A., Lewis C.E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004, 104:2224-2234.
63. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:3539-3543.
64. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
65. Howes N., Neoptolemos J.P. Risk of pancreatic ductal adenocarcinoma in chronic pancreatitis. Gut 2002, 51:765-766.
66. Ronnov-Jessen L., van Deurs B., Celis J.E., Petersen O.W. Smooth muscle differentiation in cultured human breast gland stromal cells. Lab. Invest. 1990, 63:532-543.
67. Petersen O.W., Nielsen H.L., Gudjonsson T., Villadsen R., Rank F., Niebuhr E., Bissell M.J., Ronnov-Jessen L. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am. J. Pathol. 2003, 162:391-402.
68. Spaeth E.L., Dembinski J.L., Sasser A.K., Watson K., Klopp A., Hall B., Andreeff M., Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4:e4992.
69. Mishra P.J., Humeniuk R., Medina D.J., Alexe G., Mesirov J.P., Ganesan S., Glod J.W., Banerjee D. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 2008, 68:4331-4339.
70. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276:71-74.
71. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., Zhu Z., Hicklin D., Wu Y., Port J.L., Altorki N., Port E.R., Ruggero D., Shmelkov S.V., Jensen K.K., Rafii S., Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
72. Marrache F., Pendyala S., Bhagat G., Betz K.S., Song Z., Wang T.C. Role of bone marrow-derived cells in experimental chronic pancreatitis. Gut 2008, 57:1113-1120.
73. Studeny M., Marini F.C., Dembinski J.L., Zompetta C., Cabreira-Hansen M., Bekele B.N., Champlin R.E., Andreeff M. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst. 2004, 96:1593-1603.
74. Scarlett C.J., Colvin E.K., Pinese M., Chang D.K., Morey A.L., Musgrove E.A., Pajic M., Apte M., Henshall S.M., Sutherland R.L., Kench J.G., Biankin A.V. Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. PLoS One 2011, 6:e26088.
75. Kuang C., Xiao Y., Liu X., Stringfield T.M., Zhang S., Wang Z., Chen Y. In vivo disruption of TGF-beta signaling by Smad7 leads to premalignant ductal lesions in the pancreas. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1858-1863.
76. Thayer S.P., di Magliano M.P., Heiser P.W., Nielsen C.M., Roberts D.J., Lauwers G.Y., Qi Y.P., Gysin S., Fernandez-del Castillo C., Yajnik V., Antoniu B., McMahon M., Warshaw A.L., Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425:851-856.
77. Yasui T., Ohuchida K., Zhao M., Onimaru M., Egami T., Fujita H., Ohtsuka T., Mizumoto K., Tanaka M. Tumor-stroma interactions reduce the efficacy of adenoviral therapy through the HGF-MET pathway. Cancer Sci. 2011, 102:484-491.
78. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010, 10:116-129.
79. Bergmann U., Funatomi H., Yokoyama M., Beger H.G., Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 1995, 55:2007-2011.
80. Zhu Z.W., Friess H., Wang L., Bogardus T., Korc M., Kleeff J., Buchler M.W. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells. Clin. Cancer Res. 2001, 7:105-112.
81. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
82. Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A., Wellmann A., Braunschweig T., Lohr M., Jesnowski R., Friess H., Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F., Schackert H.K., Kloppel G., Kalthoff H., Saeger H.D., Grutzmann R. Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J. Cell. Mol. Med. 2008, 12:2823-2835.
83. Ketterer K., Rao S., Friess H., Weiss J., Buchler M.W., Korc M. Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer. Clin. Cancer Res. 2003, 9:5127-5136.
84. Sato N., Fukushima N., Maehara N., Matsubayashi H., Koopmann J., Su G.H., Hruban R.H., Goggins M. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003, 22:5021-5030.
85. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2:737-744.
86. Koenig A., Mueller C., Hasel C., Adler G., Menke A. Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res. 2006, 66:4662-4671.
87. Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A., Wellmann A., Braunschweig T., Lohr M., Jesenofsky R., Friess H., Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F., Schackert H.K., Kloppel G., Kalthoff H., Saeger H.D., Grutzmann R. Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J. Cell. Mol. Med. 2008, 12:2823-2835.
88. Krantz S.B., Shields M.A., Dangi-Garimella S., Cheon E.C., Barron M.R., Hwang R.F., Rao M.S., Grippo P.J., Bentrem D.J., Munshi H.G. MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-beta signaling. Mol. Cancer Res. 2011, 9:1294-1304.
89. Ellenrieder V., Hendler S.F., Boeck W., Seufferlein T., Menke A., Ruhland C., Adler G., Gress T.M. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 2001, 61:4222-4228.
90. Tian H., Callahan C.A., DuPree K.J., Darbonne W.C., Ahn C.P., Scales S.J., de Sauvage F.J. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4254-4259.
91. Bierie B., Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6:506-520.
92. Friess H., Yamanaka Y., Buchler M., Berger H.G., Kobrin M.S., Baldwin R.L., Korc M. Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res. 1993, 53:2704-2707.
93. Lohr M., Schmidt C., Ringel J., Kluth M., Muller P., Nizze H., Jesnowski R. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 2001, 61:550-555.
94. Ohnishi H., Miyata T., Yasuda H., Satoh Y., Hanatsuka K., Kita H., Ohashi A., Tamada K., Makita N., Iiri T., Ueda N., Mashima H., Sugano K. Distinct roles of Smad2-, Smad3-, and ERK-dependent pathways in transforming growth factor-beta1 regulation of pancreatic stellate cellular functions. J. Biol. Chem. 2004, 279:8873-8878.
95. Lauth M., Toftgard R. Hedgehog signaling and pancreatic tumor development. Adv. Cancer Res. 2011, 110:1-17.
96. Berman D.M., Karhadkar S.S., Maitra A., Montes De Oca R., Gerstenblith M.R., Briggs K., Parker A.R., Shimada Y., Eshleman J.R., Watkins D.N., Beachy P.A. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003, 425:846-851.
97. Feldmann G., Dhara S., Fendrich V., Bedja D., Beaty R., Mullendore M., Karikari C., Alvarez H., Iacobuzio-Donahue C., Jimeno A., Gabrielson K.L., Matsui W., Maitra A. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007, 67:2187-2196.
98. Morris J.P.t., Wang S.C., Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 2010, 10:683-695.
99. Liu W.S., Yan H.J., Qin R.Y., Tian R., Wang M., Jiang J.X., Shen M., Shi C.J. siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig. Dis. Sci. 2009, 54:89-96.
100. Lowenfels A.B., Maisonneuve P., Cavallini G., Ammann R.W., Lankisch P.G., Andersen J.R., Dimagno E.P., Andren-Sandberg A., Domellof L. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N. Engl. J. Med. 1993, 328:1433-1437.
101. Bracci P.M., Wang F., Hassan M.M., Gupta S., Li D., Holly E.A. Pancreatitis and pancreatic cancer in two large pooled case-control studies. Cancer Causes Control 2009, 20:1723-1731.
102. Guerra C., Schuhmacher A.J., Canamero M., Grippo P.J., Verdaguer L., Perez-Gallego L., Dubus P., Sandgren E.P., Barbacid M. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007, 11:291-302.
103. Hernandez-Munoz I., Skoudy A., Real F.X., Navarro P. Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution. Pancreatology 2008, 8:462-469.
104. Longnecker D.S. Pathology and pathogenesis of diseases of the pancreas. Am. J. Pathol. 1982, 107:99-121.
105. Logsdon C.D., Simeone D.M., Binkley C., Arumugam T., Greenson J.K., Giordano T.J., Misek D.E., Kuick R., Hanash S. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003, 63:2649-2657.
106. Wittel U.A., Pandey K.K., Andrianifahanana M., Johansson S.L., Cullen D.M., Akhter M.P., Brand R.E., Prokopczyk B., Batra S.K. Chronic pancreatic inflammation induced by environmental tobacco smoke inhalation in rats. Am. J. Gastroenterol. 2006, 101:148-159.
107. van Geenen E.J., Smits M.M., Schreuder T.C., van der Peet D.L., Bloemena E., Mulder C.J. Smoking is related to pancreatic fibrosis in humans. Am. J. Gastroenterol. 2011, 106:1161-1166. quiz 1167.
108. Korc M. Pancreatic cancer-associated stroma production. Am. J. Surg. 2007, 194:S84-S86.
109. DePinho R.A. The age of cancer. Nature 2000, 408:248-254.
110. Lowenfels A.B., Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 2006, 20:197-209.
111. Krtolica A., Campisi J. Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int. J. Biochem. Cell Biol. 2002, 34:1401-1414.
112. Campisi J. Replicative senescence: an old lives' tale?. Cell 1996, 84:497-500.
113. Krtolica A., Parrinello S., Lockett S., Desprez P.Y., Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12072-12077.
114. Campisi J. Cancer and ageing: rival demons?. Nat. Rev. Cancer 2003, 3:339-349.
115. Gershengorn M.C., Hardikar A.A., Wei C., Geras-Raaka E., Marcus-Samuels B., Raaka B.M. Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. Science 2004, 306:2261-2264.
116. Stoker M., Gherardi E., Perryman M., Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987, 327:239-242.
117. Voulgari A., Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta 2009, 1796:75-90.
118. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
119. Christiansen J.J., Rajasekaran A.K. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006, 66:8319-8326.
120. Arumugam T., Ramachandran V., Fournier K.F., Wang H., Marquis L., Abbruzzese J.L., Gallick G.E., Logsdon C.D., McConkey D.J., Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69:5820-5828.
121. Singh A., Greninger P., Rhodes D., Koopman L., Violette S., Bardeesy N., Settleman J. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15:489-500.
122. Javle M.M., Gibbs J.F., Iwata K.K., Pak Y., Rutledge P., Yu J., Black J.D., Tan D., Khoury T. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann. Surg. Oncol. 2007, 14:3527-3533.
123. Nitecki S.S., Sarr M.G., Colby T.V., van Heerden J.A. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?. Ann. Surg. 1995, 221:59-66.
124. Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D.J., Buchler M.W. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004, 350:1200-1210.
125. Wang Z., Li Y., Kong D., Banerjee S., Ahmad A., Azmi A.S., Ali S., Abbruzzese J.L., Gallick G.E., Sarkar F.H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69:2400-2407.
126. Shah A.N., Summy J.M., Zhang J., Park S.I., Parikh N.U., Gallick G.E. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 2007, 14:3629-3637.
127. Mantoni T.S., Lunardi S., Al-Assar O., Masamune A., Brunner T.B., Gallick G.E. Pancreatic stellate cells radioprotect pancreatic cancer cells through beta1-integrin signaling. Cancer Res 2011, 71:3453-3458.
128. Ohuchida K., Mizumoto K., Murakami M., Qian L.W., Sato N., Nagai E., Matsumoto K., Nakamura T., Tanaka M. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res. 2004, 64:3215-3222.
129. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature 2001, 411:375-379.
130. Rowland-Goldsmith M.A., Maruyama H., Kusama T., Ralli S., Korc M. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin. Cancer Res. 2001, 7:2931-2940.
131. Takikita M., Altekruse S., Lynch C.F., Goodman M.T., Hernandez B.Y., Green M., Cozen W., Cockburn M., Sibug Saber M., Topor M., Zeruto C., Abedi-Ardekani B., Reichman M.E., Hewitt S.M. Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res. 2009, 69:2950-2955.
132. Blaine S.A., Ray K.C., Branch K.M., Robinson P.S., Whitehead R.H., Means A.L. Epidermal growth factor receptor regulates pancreatic fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 297:G434-G441.
133. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., Au H.J., Murawa P., Walde D., Wolff R.A., Campos D., Lim R., Ding K., Clark G., Voskoglou-Nomikos T., Ptasynski M., Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25:1960-1966.
134. Jones L., Ghaneh P., Humphreys M., Neoptolemos J.P. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann. N. Y. Acad. Sci. 1999, 880:288-307.
135. Moore M.J., Hamm J., Dancey J., Eisenberg P.D., Dagenais M., Fields A., Hagan K., Greenberg B., Colwell B., Zee B., Tu D., Ottaway J., Humphrey R., Seymour L. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2003, 21:3296-3302.
136. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393:478-480.
137. Luo G., Yu X., Jin C., Yang F., Fu D., Long J., Xu J., Zhan C., Lu W. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int. J. Pharm. 2010, 385:150-156.
138. Vaquero E.C., Edderkaoui M., Nam K.J., Gukovsky I., Pandol S.J., Gukovskaya A.S. Extracellular matrix proteins protect pancreatic cancer cells from death via mitochondrial and nonmitochondrial pathways. Gastroenterology 2003, 125:1188-1202.
139. Derynck R., Akhurst R.J., Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 2001, 29:117-129.
140. Hsieh C.L., Gardner T.A., Miao L., Balian G., Chung L.W. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells. Cancer Gene. Ther. 2004, 11:148-155.